An incidental lesion in a cirrhotic patient with uncertain imaging features is best managed with which next step?

Prepare for Liver Disease and Tumors Test with tailored flashcards and questions. Get detailed explanations and improve your knowledge. Ace the medical student exam!

In a cirrhotic liver, new nodules must be carefully characterized to distinguish hepatocellular carcinoma from benign regenerative or dysplastic nodules. The best next step is to obtain multiphasic MRI with contrast. This approach provides superior detail about lesion vascularity and tissue characteristics, which are crucial for accurate differentiation.

MRI uses multiple phases after contrast administration—arterial, portal venous, and delayed phases—to detect the typical pattern of hepatocellular carcinoma, which often shows rapid arterial enhancement followed by washout in later phases. Using liver-specific contrast agents can further improve accuracy by assessing hepatocyte function, helping to separate malignant lesions from benign regenerative or dysplastic nodules.

If the MRI findings are classic for HCC, biopsy is usually not required and management proceeds according to HCC guidelines. If the MRI result is indeterminate, a biopsy may be considered, but it is not the immediate first step because sampling can miss the diagnosis and carries risks such as tumor seeding. Starting chemotherapy would be inappropriate without a confirmed diagnosis, and skipping further workup could miss a treatable lesion.

So, the goal is to noninvasively and accurately characterize the lesion with MRI to guide safe and appropriate management.